International Assets Investment Management LLC Raises Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

International Assets Investment Management LLC raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 51,631.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 547,834 shares of the company's stock after acquiring an additional 546,775 shares during the period. International Assets Investment Management LLC owned approximately 0.66% of IDEXX Laboratories worth $304,075,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Moneta Group Investment Advisors LLC raised its holdings in shares of IDEXX Laboratories by 121,647.2% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company's stock valued at $3,038,192,000 after acquiring an additional 7,441,162 shares in the last quarter. State Street Corp increased its position in shares of IDEXX Laboratories by 2.6% during the 2nd quarter. State Street Corp now owns 3,771,574 shares of the company's stock valued at $1,894,198,000 after purchasing an additional 97,303 shares during the last quarter. Alliancebernstein L.P. increased its position in shares of IDEXX Laboratories by 6.4% during the 2nd quarter. Alliancebernstein L.P. now owns 3,592,832 shares of the company's stock valued at $1,804,428,000 after purchasing an additional 214,529 shares during the last quarter. Geode Capital Management LLC increased its position in shares of IDEXX Laboratories by 1.4% during the 1st quarter. Geode Capital Management LLC now owns 1,946,339 shares of the company's stock valued at $971,569,000 after purchasing an additional 26,197 shares during the last quarter. Finally, Blair William & Co. IL increased its position in shares of IDEXX Laboratories by 0.7% during the 3rd quarter. Blair William & Co. IL now owns 1,199,945 shares of the company's stock valued at $524,700,000 after purchasing an additional 7,812 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Insider Transactions at IDEXX Laboratories

In other news, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the sale, the senior vice president now directly owns 6,712 shares in the company, valued at approximately $3,851,815.44. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, SVP George Fennell sold 8,198 shares of the firm's stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now owns 6,712 shares in the company, valued at approximately $3,851,815.44. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Brian P. Mckeon sold 23,326 shares of the firm's stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the completion of the transaction, the chief financial officer now owns 29,718 shares of the company's stock, valued at approximately $16,939,557.18. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,524 shares of company stock worth $24,871,960. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Trading Up 0.3 %

Shares of IDXX stock traded up $1.44 during trading hours on Friday, reaching $519.54. The company's stock had a trading volume of 434,869 shares, compared to its average volume of 423,222. The stock has a market capitalization of $43.15 billion, a P/E ratio of 51.59, a P/E/G ratio of 2.87 and a beta of 1.26. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The firm's fifty day simple moving average is $548.67 and its 200 day simple moving average is $504.48. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.42.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, topping analysts' consensus estimates of $2.12 by $0.20. The firm had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The business's quarterly revenue was up 8.8% compared to the same quarter last year. During the same period last year, the company earned $2.05 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 11.15 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on IDXX. The Goldman Sachs Group increased their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the company a "buy" rating in a research report on Wednesday, January 17th. BNP Paribas began coverage on IDEXX Laboratories in a research report on Thursday, December 7th. They set an "outperform" rating and a $602.00 price objective on the stock. Barclays increased their price objective on IDEXX Laboratories from $605.00 to $655.00 and gave the company an "overweight" rating in a research report on Tuesday, February 6th. Piper Sandler lowered IDEXX Laboratories from an "overweight" rating to a "neutral" rating and set a $525.00 price objective on the stock. in a research report on Tuesday, January 30th. Finally, JPMorgan Chase & Co. raised their price target on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $591.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.